M Naveed Shaik

List of Publications by Year
in descending order

33	2,102	361296	434063
papers	citations	20	31
		h-index	g-index

34	34	34	2810
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical and Modelâ€Based Evaluation of the Effect of Glasdegib on Cardiac Repolarization From a Randomized Thorough QT Study. Clinical Pharmacology in Drug Development, 2021, 10, 272-282.	0.8	3
2	Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies. Journal of Clinical Pharmacology, 2021, 61, 349-359.	1.0	2
3	Exposureâ€"response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer. Expert Review of Clinical Pharmacology, 2021, 14, 927-935.	1.3	2
4	Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers. Cancer Chemotherapy and Pharmacology, 2021, 87, 241-250.	1.1	2
5	Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Singleâ€Dose, Matched Caseâ€Control Study. Clinical Pharmacology in Drug Development, 2021, 10, 707-717.	0.8	4
6	Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors. Journal of Clinical Pharmacology, 2020, 60, 605-616.	1.0	13
7	An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure. Cancer Chemotherapy and Pharmacology, 2020, 86, 451-459.	1.1	6
8	Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. Future Oncology, 2019, 15, 3531-3545.	1.1	38
9	Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. Leukemia Research, 2019, 79, 38-44.	0.4	25
10	Absolute Oral Bioavailability of Glasdegib (PFâ€04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers. Clinical Pharmacology in Drug Development, 2019, 8, 895-902.	0.8	8
11	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia, 2019, 33, 379-389.	3.3	396
12	Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study. Cancer Chemotherapy and Pharmacology, 2019, 83, 463-472.	1.1	17
13	Abstract 3887: Population pharmacokinetic/pharmacodynamic evaluation of the relationship between glasdegib exposure and safety endpoints in cancer patients. , 2019, , .		1
14	Abstract 3889: Population pharmacokinetic/pharmacodynamic evaluation of the effect of glasdegib exposure on cardiac repolarization (QT interval) in cancer patients. , 2019, , .		1
15	Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clinical Cancer Research, 2018, 24, 2294-2303.	3.2	87
16	Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers. British Journal of Clinical Pharmacology, 2018, 84, 1346-1353.	1.1	20
17	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or highâ€risk MDS: Phase 2 study results. American Journal of Hematology, 2018, 93, 1301-1310.	2.0	98
18	Population Pharmacokinetic/Pharmacodynamic Evaluation of the Relationship between Glasdegib Treatment/ Exposure and Overall Survival in AML Patients. Blood, 2018, 132, 1450-1450.	0.6	5

#	Article	IF	Citations
19	Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers. Cancer Chemotherapy and Pharmacology, 2017, 80, 1249-1260.	1.1	12
20	Metabolism, excretion and pharmacokinetics of [¹⁴C]glasdegib (PF-04449913) in healthy volunteers following oral administration. Xenobiotica, 2017, 47, 1064-1076.	0.5	21
21	A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. Blood, 2016, 128, 99-99.	0.6	36
22	Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematology,the, 2015, 2, e339-e346.	2.2	102
23	A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 1044-1051.	3.2	61
24	Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers. Cancer Chemotherapy and Pharmacology, 2014, 74, 411-418.	1.1	31
25	Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer. Clinical Cancer Research, 2012, 18, 568-576.	3.2	323
26	Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood, 2012, 119, 4597-4607.	0.6	278
27	Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies. Blood, 2011, 118, 424-424.	0.6	33
28	Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design. Drug Metabolism and Disposition, 2009, 37, 560-570.	1.7	69
29	P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 956-963.	1.3	181
30	Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: Cell accumulation and equilibrium dialysis studies. Journal of Pharmaceutical Sciences, 2009, 98, 4170-4190.	1.6	26
31	Interactions of pluronic block copolymers on Pâ€gp efflux activity: Experience with HIVâ€1 protease inhibitors. Journal of Pharmaceutical Sciences, 2008, 97, 5421-5433.	1.6	51
32	Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) on Pharmacokinetics and Central Nervous System Penetration of Abacavir and Zidovudine in the Mouse. Drug Metabolism and Disposition, 2008, 36, 1476-1484.	1.7	67
33	P-glycoprotein-Mediated Active Efflux of the Anti-HIV1 Nucleoside Abacavir Limits Cellular Accumulation and Brain Distribution. Drug Metabolism and Disposition, 2007, 35, 2076-2085.	1.7	83